205 related articles for article (PubMed ID: 38461299)
1. Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation.
Li C; Wang Z; Yao L; Lin X; Jian Y; Li Y; Zhang J; Shao J; Tran PD; Hagman JR; Cao M; Cong Y; Li HY; Goding CR; Xu ZX; Liao X; Miao X; Cui R
Nat Commun; 2024 Mar; 15(1):2163. PubMed ID: 38461299
[TBL] [Abstract][Full Text] [Related]
2. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract][Full Text] [Related]
3. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.
Zingg D; Arenas-Ramirez N; Sahin D; Rosalia RA; Antunes AT; Haeusel J; Sommer L; Boyman O
Cell Rep; 2017 Jul; 20(4):854-867. PubMed ID: 28746871
[TBL] [Abstract][Full Text] [Related]
4. H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade.
Hoffmann F; Niebel D; Aymans P; Ferring-Schmitt S; Dietrich D; Landsberg J
Clin Epigenetics; 2020 Feb; 12(1):24. PubMed ID: 32041674
[TBL] [Abstract][Full Text] [Related]
5. EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice.
Wu L; Jiang X; Qi C; Zhang C; Qu B; Shen N
Front Immunol; 2021; 12():653989. PubMed ID: 33868295
[TBL] [Abstract][Full Text] [Related]
6. EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma.
Xu T; Dai J; Tang L; Yang L; Si L; Sheng X; Cui C; Chi Z; Kong Y; Guo J
J Invest Dermatol; 2022 Apr; 142(4):1158-1170.e8. PubMed ID: 34571002
[TBL] [Abstract][Full Text] [Related]
7. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
Sun S; Yu F; Xu D; Zheng H; Li M
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma.
Filipski K; Scherer M; Zeiner KN; Bucher A; Kleemann J; Jurmeister P; Hartung TI; Meissner M; Plate KH; Fenton TR; Walter J; Tierling S; Schilling B; Zeiner PS; Harter PN
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281986
[TBL] [Abstract][Full Text] [Related]
9. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.
Uebel A; Kewitz-Hempel S; Willscher E; Gebhardt K; Sunderkötter C; Gerloff D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768289
[TBL] [Abstract][Full Text] [Related]
10. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.
Mahmoud F; Shields B; Makhoul I; Hutchins LF; Shalin SC; Tackett AJ
Cancer Biol Ther; 2016 Jun; 17(6):579-91. PubMed ID: 27105109
[TBL] [Abstract][Full Text] [Related]
11. Chromatin restriction by the nucleosome remodeler Mi-2β and functional interplay with lineage-specific transcription regulators control B-cell differentiation.
Yoshida T; Hu Y; Zhang Z; Emmanuel AO; Galani K; Muhire B; Snippert HJ; Williams CJ; Tolstorukov MY; Gounari F; Georgopoulos K
Genes Dev; 2019 Jul; 33(13-14):763-781. PubMed ID: 31123064
[TBL] [Abstract][Full Text] [Related]
12. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
Eich ML; Athar M; Ferguson JE; Varambally S
Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
[TBL] [Abstract][Full Text] [Related]
13. GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers.
Ko HW; Lee HH; Huo L; Xia W; Yang CC; Hsu JL; Li LY; Lai CC; Chan LC; Cheng CC; Labaff AM; Liao HW; Lim SO; Li CW; Wei Y; Nie L; Yamaguchi H; Hung MC
Oncotarget; 2016 Aug; 7(35):57131-57144. PubMed ID: 27494834
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo.
Zhu Y; Zhang L; Song X; Zhang Q; Wang T; Xiao H; Yu L
Biochem Pharmacol; 2023 Apr; 210():115493. PubMed ID: 36898415
[TBL] [Abstract][Full Text] [Related]
15. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of Zeste Homolog 2 Inhibition Stimulates Bone Formation and Mitigates Bone Loss Caused by Ovariectomy in Skeletally Mature Mice.
Dudakovic A; Camilleri ET; Riester SM; Paradise CR; Gluscevic M; O'Toole TM; Thaler R; Evans JM; Yan H; Subramaniam M; Hawse JR; Stein GS; Montecino MA; McGee-Lawrence ME; Westendorf JJ; van Wijnen AJ
J Biol Chem; 2016 Nov; 291(47):24594-24606. PubMed ID: 27758858
[TBL] [Abstract][Full Text] [Related]
17.
Quentmeier H; Pommerenke C; Hauer V; Uphoff CC; Zaborski M; Drexler HG
Leuk Lymphoma; 2020 Dec; 61(12):2885-2893. PubMed ID: 32715799
[No Abstract] [Full Text] [Related]
18. DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Ressler JM; Tomasich E; Hatziioannou T; Ringl H; Heller G; Silmbrod R; Gottmann L; Starzer AM; Zila N; Tschandl P; Hoeller C; Preusser M; Berghoff AS
Target Oncol; 2024 Mar; 19(2):263-275. PubMed ID: 38401029
[TBL] [Abstract][Full Text] [Related]
19. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
20. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
